c-MET (L1195F)

MET · Variant type: point · HGVS: p.L1195F

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Tepotinib	95.4%	4.6%	99.75
2	Capmatinib	92.9%	7.1%	99.75
3	Tivozanib	91.0%	9.0%	92.42
4	Gilteritinib	87.7%	12.3%	88.97
5	Pacritinib	79.9%	20.1%	88.64
6	Defactinib	69.4%	30.6%	92.68
7	Deucravacitinib	61.7%	38.3%	98.99
8	Repotrectinib	60.5%	39.5%	84.21
9	Neratinib	55.1%	44.9%	93.18
10	Selpercatinib	51.4%	48.6%	96.72
11	Abemaciclib	39.7%	60.3%	91.48
12	Canertinib	36.3%	63.7%	96.49
13	Sunitinib	32.7%	67.3%	91.73
14	Entrectinib	31.2%	68.8%	93.69
15	Fedratinib	29.1%	70.9%	96.21
16	Avapritinib	24.4%	75.6%	97.73
17	Erdafitinib	17.9%	82.1%	95.71
18	Pexidartinib	15.1%	84.9%	99.49
19	Vandetanib	13.5%	86.5%	95.74
20	Abrocitinib	12.3%	87.7%	99.50
21	Pemigatinib	8.3%	91.7%	98.23
22	Ripretinib	7.0%	93.0%	92.95
23	Lazertinib	6.4%	93.6%	97.47
24	Acalabrutinib	5.7%	94.3%	99.50
25	Pirtobrutinib	5.4%	94.6%	99.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Tepotinib	95.4%	—	—
Capmatinib	92.9%	—	—
Tivozanib	91.0%	—	—
Gilteritinib	87.7%	—	—
Pacritinib	79.9%	—	—
Defactinib	69.4%	—	—
Deucravacitinib	61.7%	—	—
Repotrectinib	60.5%	—	—
Neratinib	55.1%	—	—
Selpercatinib	51.4%	—	—
Abemaciclib	39.7%	—	—
Canertinib	36.3%	—	—
Sunitinib	32.7%	—	—
Entrectinib	31.2%	—	—
Fedratinib	29.1%	—	—
Avapritinib	24.4%	—	—
Erdafitinib	17.9%	—	—
Pexidartinib	15.1%	—	—
Vandetanib	13.5%	—	—
Abrocitinib	12.3%	—	—
Pemigatinib	8.3%	—	—
Ripretinib	7.0%	—	—
Lazertinib	6.4%	—	—
Acalabrutinib	5.7%	—	—
Pirtobrutinib	5.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.8ms